See the DrugPatentWatch profile for Tavalisse
What patent litigation is Rigel Pharmaceuticals involved in with Tavalisse, and what is the March 2025 reference?
There are no details in the provided information about any specific “Tavalisse patent litigation” involving Rigel Pharmaceuticals, nor any facts tied to “March 2025.” To answer accurately (for example, which patents are at issue, what court or jurisdiction is involved, and what happened in or around March 2025), I would need at least one supporting source such as a news article link, a docket number, a press release, or the specific patent(s) referenced.
What I need from you to identify the right case
If you share any of the following, I can synthesize the litigation timeline and key claims precisely:
- A link to the article/post mentioning “March 2025”
- The court (e.g., Delaware, D.C. District Court, ITC, etc.) or case caption
- A docket number
- The patent numbers or the drug/term the patent covers (for example, use patents vs. composition vs. formulation)
- Whether the dispute is about ANDA/Section 505(b)(2) or another patent-approval pathway
Why this is hard to answer without a source
“Tavalisse” (fostamatinib) has had multiple commercial and regulatory developments over time, and Rigel-related matters can involve different IP theories and different procedural stages. Without the specific March 2025 reference, it’s not possible to reliably identify:
- which asserted patent(s) were involved,
- whether Rigel is the plaintiff or defendant,
- whether the matter is an infringement suit, a patent-challenge/approval case, or a related proceeding,
- and what the March 2025 event actually was (filing, ruling, settlement, stay, or appeal).
Send the citation and I’ll summarize it
Paste the text you’re looking at (even a short excerpt) or provide a URL, and I’ll produce a tight summary covering:
- parties and venue,
- patents-in-suit,
- what each side alleges,
- what the March 2025 event was,
- current procedural posture and likely next steps,
- and any implications for generic/biosimilar entry timing if that’s part of the story.
Sources
No sources were provided.